Dermatological manifestations of inherited cancer syndromes in children

British Journal of Dermatology

Volumn 164, Issue 2, 2011, Pages 245-256

  Karalis, A ^a,b   Tischkowitz, M ^a,c   Millington, George W M ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ALBRIGHT SYNDROME; ATAXIA TELANGIECTASIA; BASAL CELL NEVUS SYNDROME; BECKWITH WIEDEMANN SYNDROME; BLOOM SYNDROME; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CARNEY COMPLEX; CELL CYCLE REGULATION; CHEDIAK HIGASHI SYNDROME; CHILD; CLINICAL FEATURE; COSTELLO SYNDROME; DISEASE PREDISPOSITION; DNA DAMAGE; DNA REPAIR; DYSKERATOSIS CONGENITA; FAMILY HISTORY; FANCONI ANEMIA; GAUCHER DISEASE; GENETIC COUNSELING; GENETIC SCREENING; HETEROZYGOTE; HUMAN; HUNTER SYNDROME; JUVENILE XANTHOGRANULOMA; LEGIUS SYNDROME; LEOPARD SYNDROME; MARFAN SYNDROME; MISMATCH REPAIR; MOLECULAR RECOGNITION; MOLECULAR TYPING; MULTIPLE ENDOCRINE NEOPLASIA; NAIL PATELLA SYNDROME; NEUROBLASTOMA; NEUROFIBROMATOSIS; PEUTZ JEGHERS SYNDROME; PHENOTYPE; PHYSICIAN; PRIORITY JOURNAL; REVIEW; RING CHROMOSOME; ROTHMUND THOMSON SYNDROME; SILVER RUSSELL SYNDROME; SKIN MANIFESTATION; TUBEROUS SCLEROSIS; WERNER SYNDROME; WISKOTT ALDRICH SYNDROME; X LINKED AGAMMAGLOBULINEMIA; XERODERMA PIGMENTOSUM;

CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; MALE; NEOPLASTIC SYNDROMES, HEREDITARY; SKIN DISEASES; SYNDROME;

EID: 79551490927     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10100.x     Document Type: Review

References (101)

1. Foulkes WD,. Inherited susceptibility to common cancers. N Engl J Med 2008; 359: 2143-53.
2. Al Fares A, Millington GWM, Tischkowitz M,. Dermatological manifestations of inherited cancer syndromes in adults. Clin Exp Dermatol 2010; 35: 462-7.
3. Tischkowitz M, Rosser E,. Inherited cancer in children: practical/ethical problems and challenges. Eur J Cancer 2004; 40: 2459-70.
4. Tsao H,. Update on familial cancer syndromes and the skin. J Am Acad Dermatol 2000; 42: 939-69.
5. McKinnon PJ, Caldecott KW,. DNA strand break repair and human genetic disease. Annu Rev Genomics Hum Genet 2007; 8: 37-55.
6. Hoeijmakers JHJ,. DNA damage, aging, and cancer. N Engl J Med 2009; 361: 1475-85.
7. Lo Muzio L,. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis 2008; 3: 32.
8. Rauen KA,. HRAS and the Costello syndrome. Clin Genet 2007; 71: 101-8.
9. Abrams M, Paller A,. Genetic immunodeficiency diseases. Adv Dermatol 2007; 23: 197-229.
10. Terdiman JP,. MYH-associated disease: attenuated adenomatous polyposis of the colon is only part of the story. Gastroenterology 2009; 137: 1883-6.
11. Wimmer K, Etzler J,. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet 2008; 124: 105-22.
12. Krüger S, Kinzel M, Walldorf C, et al. Homozygous PMS2 germline mutations in two families with early-onset haematological malignancy, brain tumours, HNPCC-associated tumours, and signs of neurofibromatosis type 1. Eur J Hum Genet 2008; 16: 62-72.
13. Kratz CP, Holter S, Etzler J, et al. Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome. J Med Genet 2009; 46: 418-20.
14. De Vos M, Hayward BE, Picton S, et al. Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am J Hum Genet 2004; 74: 954-64.
15. Kraemer KH, Lee MM, Scotto J,. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987; 123: 241-50.
16. Kraemer KH, Patronas NJ, Schiffmann R, et al. Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a complex genotype-phenotype relationship. Neuroscience 2007; 145: 1388-96.
17. Lichon V, Khachemoune A,. Xeroderma pigmentosum: beyond skin cancer. J Drugs Dermatol 2007; 6: 281-8.
18. Kato T, Akiba H, Seiji M, et al. Clinical and biological studies of 26 cases of xeroderma pigmentosum in northeast district of Japan. Arch Dermatol Res 1985; 277: 1-7.
19. Liu Y,. Rothmund-Thomson syndrome helicase, RECQ4: on the crossroad between DNA replication and repair. DNA Repair 2010; 9: 325-30.
20. Wang LL, Levy ML, Lewis RA, et al. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet 2001; 102: 11-17.
21. Stinco G, Governatori G, Mattighello P, Patrone P,. Multiple cutaneous neoplasms in a patient with Rothmund-Thomson syndrome: case report and published work review. J Dermatol 2008; 35: 154-61.
22. Soulier J, Leblanc T, Larghero J, et al. Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. Blood 2005; 105: 1329-36.
23. Tischkowitz M, Dokal I,. Fanconi anaemia and leukaemia-clinical and molecular aspects. Br J Haematol 2004; 126: 176-91.
24. De Kerviler E, Guermazi A, Zagdanski AM, et al. The clinical and radiological features of Fanconi's anaemia. Clin Radiol 2000; 55: 340-5.
25. de Araujo MR, de Oliveira Ribas M, Koubik AC, et al. Fanconi's anemia: clinical and radiographic oral manifestations. Oral Dis 2007; 13: 291-5.
26. Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003; 101: 1249-56.
27. Alter BP,. Cancer in Fanconi anemia, 1927-2001. Cancer 2003; 97: 425-40.
28. Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007; 39: 162-4.
29. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007; 39: 165-7.
30. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010; 42: 410-14.
31. Vaz F, Hanenberg H, Schuster B, et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 2010; 42: 406-9.
32. Kastan K,. Clinical implications of basic research: ataxia- telangiectasia-broad implications for a rare disorder. N Engl J Med 1995; 333: 662-3.
33. Finsterer J,. Ataxias with autosomal, X-chromosomal or maternal inheritance. Can J Neurol Sci 2009; 36: 409-28.
34. Stray-Pedersen A, Borresen-Dale AL, Paus E, et al. Alpha fetoprotein is increasing with age in ataxia-telangiectasia. Eur J Paediatr Neurol 2007; 11: 375-80.
35. Khumalo NP, Joss DV, Huson SM, Burge S,. Pigmentary anomalies in ataxia-telangiectasia: a clue to diagnosis and an example of twin spotting. Br J Dermatol 2001; 144: 369-71.
36. Cohen LE, Tanner DJ, Schaefer HG, Levis WR,. Common and uncommon cutaneous findings in patients with ataxia-telangiectasia. J Am Acad Dermatol 1984; 10: 431-8.
37. Sari A, Okuyaz C, Adiguzel U, Ates NA,. Uncommon associations with ataxia-telangiectasia: vitiligo and optic disc drusen. Ophthalmic Genet 2009; 30: 19-22.
38. Ivonye C, Jamched U, Anderson D, Adesunloye B,. Uncommon skin lesion in a patient with ataxia-telangiectasia. Int J Dermatol 2008; 47: 1051-2.
39. Su Y, Swift M,. Mortality rates among carriers of ataxia-telangiectasia mutant alleles. Ann Intern Med 2000; 133: 770-8.
40. Thompson D, Duedal S, Kirner J, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005; 97: 813-22.
41. Renwick A, Thompson D, Seal S, et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006; 38: 873-5.
42. Kaneko H, Kondo N,. Clinical features of Bloom syndrome and function of the causative gene, BLM helicase. Expert Rev Mol Diagn 2004; 4: 393-401.
43. Poppe B, van Limbergen H, van Roy N, et al. Chromosomal aberrations in Bloom syndrome patients with myeloid malignancies. Cancer Genet Cytogenet 2001; 128: 39-42.
44. Muftuoglu M, Oshima J, von Kobbe C, et al. The clinical characteristics of Werner syndrome: molecular and biochemical diagnosis. Hum Genet 2008; 124: 369-77.
45. Goldsmith LA,. Genetic skin diseases with altered aging. Arch Dermatol 1997; 133: 1293-5.
46. Huang S, Lee L, Hanson NB, et al. The spectrum of WRN mutations in Werner syndrome patients. Hum Mutat 2006; 27: 558-67.
47. Millington GWM,. Epigenetics and dermatological disease. Pharmacogenomics 2008; 9: 1835-50.
48. Lupi O,. Correlations between the Sonic Hedgehog pathway and basal cell carcinoma. Int J Dermatol 2007; 46: 1113-17.
49. Winship IM, Dudding TE,. Lessons from the skin-cutaneous features of familial cancer. Lancet Oncol 2008; 9: 462-72.
50. Evans DG, Ladusans EJ, Rimmer S, et al. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet 1993; 30: 460-4.
51. Shanley S, Ratcliffe J, Hockey A, et al. Nevoid basal cell carcinoma syndrome: review of 118 affected individuals. Am J Med Genet 1994; 50: 282-90.
52. Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet 1997; 69: 299-308.
53. Crawford JR, Rood BR, Rossi CT, Vezina G,. Medulloblastoma associated with novel PTCH mutation as primary manifestation of Gorlin syndrome. Neurology 2009; 72: 1618.
54. Tidyman WE, Rauen KA,. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway. Expert Rev Mol Med 2008; 10: e37.
55. Denayer E, Legius E,. What's new in the neuro-cardio-facial-cutaneous syndromes? Eur J Pediatr 2007; 166: 1091-8.
56. Gripp KW,. Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet 2005; 137C: 72-7.
57. Boyd KP, Korf BR, Theos A,. Neurofibromatosis type 1. J Am Acad Dermatol 2009; 61: 1-4.
58. Millington GWM,. Genomic imprinting and dermatological disease. Clin Exp Dermatol 2006; 31: 681-8.
59. Brems H, Chmara M, Sahbatou M, et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 2007; 39: 1120-6.
60. Pasmant E, Ballerini P, Lapillonne H, et al. SPRED1 disorder and predisposition to leukemia in children. Blood 2009; 114: 1131.
61. Curto M, McClatchey AI,. Nf2/Merlin: a coordinator of receptor signalling and intercellular contact. Br J Cancer 2008; 98: 256-62.
62. Ko JY, Kim JE, Kim YH, Ro YS,. Cutaneous plexiform schwannomas in a patient with neurofibromatosis type 2. Ann Dermatol 2009; 21: 402-5.
63. Orlova KA, Crino PB,. The tuberous sclerosis complex. Ann NY Acad Sci 2010; 1184: 87-105.
64. Schussheim DH, Skarulis MC, Agarwal SK, et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 2001; 12: 173-8.
65. Vidal A, Iglesias MJ, Fernández B, et al. Cutaneous lesions associated to multiple endocrine neoplasia syndrome type 1. J Eur Acad Dermatol Venereol 2008; 22: 835-8.
66. Raue F, Frank-Raue K,. Update multiple endocrine neoplasia type 2. Fam Cancer 2010; 9: 449-57.
67. Baykal C, Buyukbabani N, Boztepe H, et al. Multiple cutaneous neuromas and macular amyloidosis associated with medullary thyroid carcinoma. J Am Acad Dermatol 2007; 56 (Suppl.): S33-7.
68. Verga U, Fugazzola L, Cambiaghi S, et al. Frequent association between MEN 2A and cutaneous lichen amyloidosis. Clin Endocrinol 2003; 59: 156-61.
69. Tanaka A, Lai-Cheong JE, van den Akker PC, et al. The molecular skin pathology of familial primary localized cutaneous amyloidosis. Exp Dermatol 2010; 19: 416-23.
70. Duquia RP, de Almeida HL, Traesel M, Jannke HA,. Cutaneous metastasis of pheochromocytoma in multiple endocrine neoplasia IIB. J Am Acad Dermatol 2006; 55: 341-4.
71. Horvath A, Stratakis CA,. Carney complex and lentiginosis. Pigment Cell Melanoma Res 2009; 22: 580-7.
72. Matyakhina L, Pack S, Kirschner LS, et al. Chromosome 2 (2p16) abnormalities in Carney complex tumours. J Med Genet 2003; 40: 268-77.
73. Biliya S, Bulla LA,. Genomic imprinting: the influence of differential methylation in the two sexes. Exp Biol Med 2010; 235: 139-47.
74. DeBaun MR, Tucker MA,. Risk of cancer during first four years of life in children with Beckwith-Wiedemann syndrome. J Pediatr 1998; 132: 398-400.
75. Arbiser JL,. Genetic immunodeficiencies: cutaneous manifestations and recent progress. J Am Acad Dermatol 1995; 33: 82-9.
76. Bosticardo M, Marangoni F, Aiuti A, et al. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood 2009; 113: 6288-95.
77. Fernando HS, Kynaston HG, Jiang WG,. WASP and WAVE proteins: vital intrinsic regulators of cell motility and their role in cancer. Int J Mol Med 2009; 23: 141-8.
78. Kaplan J, De Domenico I, Ward DM,. Chediak-Higashi syndrome. Curr Opin Hematol 2008; 15: 22-9.
79. Hayes TC,. Acquired Chediak-Higashi anomaly in a case of acute lymphoblastic leukemia. Pediatr Dev Pathol 1999; 2: 600-1.
80. Argyle JC, Kjeldsberg CR, Marty J, et al. T-cell lymphoma and the Chediak-Higashi syndrome. Blood 1982; 60: 672-6.
81. Ochs HD, Smith CI,. X-linked agammaglobulinemia. A clinical and molecular analysis. Medicine (Baltimore) 1996; 75: 287-99.
82. Hunter HL, McKenna KE, Edgar JDM,. Eczema and X-linked agammaglobulinaemia. Clin Exp Dermatol 2008; 33: 148-50.
83. Brosens LA, Tytgat KM, Morsink FH, et al. Multiple colorectal neoplasms in X-linked agammaglobulinemia. Clin Gastroenterol Hepatol 2008; 6: 115-19.
84. Bachmeyer C, Monge M, Cazier A, et al. Gastric adenocarcinoma in a patient with X-linked agammaglobulinaemia. Eur J Gastroenterol Hepatol 2000; 12: 1033-5.
85. Kirwan M, Dokal I,. Dyskeratosis congenita: a genetic disorder of many faces. Clin Genet 2008; 73: 103-12.
86. Alter BP, Giri N, Savage SA, Rosenberg PS,. Cancer in dyskeratosis congenita. Blood 2009; 113: 6549-57.
87. Oberthuer A, Theissen J, Westermann F, et al. Molecular characterization and classification of neuroblastoma. Future Oncol 2009; 5: 625-39.
88. Gunes T, Akcakus M,. Congenital neuroblastoma with cutaneous metastases. Indian Pediatr 2002; 39: 308.
89. Chatten J, Voorhees ML,. Familial neuroblastoma. Report of a kindred with multiple disorders, including neuroblastomas in four siblings. N Engl J Med 1967; 277: 1230-6.
90. Bongers EMHF, de Wijs IJ, Marcelis C, et al. Identification of entire LMX1B gene deletions in nail patella syndrome: evidence for haploinsufficiency as the main pathogenic mechanism underlying dominant inheritance in man. Eur J Hum Genet 2008; 16: 1240-4.
91. Gilula LA, Kantor OS,. Familial colon carcinoma in nail-patella syndrome. Am J Roentgenol Radium Ther Nucl Med 1975; 123: 783-90.
92. Ortonne JP, Brocard E, Floret D, et al. Diagnostic value of café-au-lait spots. Ann Dermatol Venereol 1980; 107: 313-27.
93. Landau M, Krafchik BR,. The diagnostic value of café-au-lait macules. J Am Acad Dermatol 1999; 40: 877-9.
94. Watson GH,. Pulmonary stenosis, cafe-au-lait spots, and dull intelligence. Arch Dis Child 1967; 42: 303-7.
95. Digilio MC, Sarkozy A, de Zorzi A, et al. LEOPARD syndrome: clinical diagnosis in the first year of life. Am J Med Genet 2006; 140A: 740-6.
96. Pandit B, Sarkozy A, Pennacchio LA, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 2007; 39: 1007-12.
97. Le Meur N, Martin C, Saugier-Veber P, et al. Complete germline deletion of the STK11 gene in a family with Peutz-Jeghers syndrome. Eur J Hum Genet 2004; 12: 415-18.
98. Turner JA, Stanley NN,. Fragile lung in the Marfan syndrome. Thorax 1976; 31: 771-5.
99. Zen PR, Pinto LL, Graziadio C, et al. Association of microcephaly and café-au-lait spots in a patient with ring chromosome 12 syndrome. Clin Dysmorphol 2005; 14: 141-3.
100. Thami GP, Kaur S, Kanwar AJ,. Association of juvenile xanthogranuloma with café-au-lait macules. Int J Dermatol 2001; 40: 283-5.
101. Hoeijmakers JH,. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-74.